About: SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc
Creator	Magro, Giuseppe
source	Elsevier; Medline; PMC
abstract	Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1016/j.cytox.2020.100029
bibo:pmid	32421092
has license	no-cc
sha1sum (hex)	c33a3b9c94743d9702fee86ffe707b01366ad511
schema:url	https://doi.org/10.1016/j.cytox.2020.100029
resource representing a document's title	SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc
has PubMed Central identifier	PMC7224649
has PubMed identifier	32421092
schema:publication	Cytokine X
resource representing a document's body	covid:c33a3b9c94743d9702fee86ffe707b01366ad511#body_text
is schema:about of	named entity 'cytokines' named entity 'IL-6' named entity 'outbreak' named entity 'published' named entity 'cytokines' named entity 'Tocilizumab' named entity 'COVID-19' named entity 'IL-6' named entity 'IL-6' named entity 'cytokines' named entity 'secretion' named entity 'lesion' named entity 'COVID-19' named entity 'Tocilizumab' named entity 'patients' named entity 'fibroblast' named entity 'lung' named entity 'cytokine secretion' named entity 'monocytes' named entity 'IL-6' named entity 'chronic inflammatory diseases' named entity 'murine' named entity 'IL-1beta' named entity 'IL-6' named entity 'immune dysregulation' named entity 'granulocytes' named entity 'ruxolitinib' named entity 'endothelial cells' named entity 'single stranded RNA' named entity 'ARDS' named entity 'JAK-STAT' named entity 'signaling pathways' named entity 'animal models' named entity 'IL-6' named entity 'endothelial cells' named entity 'kinase' named entity 'polycythemia vera' named entity 'ARDS' named entity 'influenza' named entity 'influenza' named entity 'human body' named entity 'proinflammatory' named entity 'inflammatory response' named entity 'SARS-CoV-1' named entity 'arteriolar walls' named entity 'IL-6R' named entity 'SARS-CoV-1' named entity 'membrane bound' named entity 'Gp130' named entity 'Interferon beta' named entity 'D-Dimer' named entity 'signaling pathway' named entity 'protein' named entity 'IL1B' named entity 'protein' named entity 'COVID' named entity 'IL-6' named entity 'SARS-CoV-2' named entity 'South Arabia' named entity 'nucleus' named entity 'IL-6' named entity 'inflammatory cytokines' named entity 'SARS-CoV-1' named entity 'stromal cells' named entity 'C-terminus' named entity 'mitogen-activated protein kinase' named entity 'transcription factors' named entity 'infection' named entity 'mRNA' named entity 'IL-6 inhibitor' named entity 'SARS-CoV-2' named entity 'TLRs' named entity 'Macrophage Activation Syndrome' named entity 'influenza A virus' named entity 'neuroinflammation' named entity 'ADAM17' named entity 'ALI' named entity 'mice' named entity 'IL-6' named entity 'pro-inflammatory' named entity 'chronic lymphocytic leukemia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software